# Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

> **NCT00993447** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 600 (actual)

## Conditions studied

- Dengue
- Dengue Hemorrhagic Fever
- Dengue Virus
- Dengue Fever

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis

## Key facts

- **NCT ID:** NCT00993447
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-09
- **Final completion:** 2012-03
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993447, "Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00993447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*